Fuchs Endothelial Dystrophy (FED) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Fuchs Endothelial Dystrophy (FED) Market Outlook

Thelansis’s “Fuchs Endothelial Dystrophy (FED) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Fuchs Endothelial Dystrophy (FED) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Fuchs Endothelial Dystrophy (FED) Overview

Fuchs endothelial dystrophy (FED) is a primary, progressive corneal endothelial disorder that causes corneal edema and vision loss. The first signs of FED usually appear between the fifth and seventh decades of life. They are characterized by progressive accumulation of focal excrescences, termed “guttae,” and thickening of Descemet’s membrane, a collagen-rich layer secreted by endothelial cells. Endothelial cell density and functionality as the cornea's "pump" eventually decline, resulting in vision-threatening corneal edema. Although the presence of corneal guttae is not pathognomonic for FED, the development of stromal edema does. Symptoms include visual blurring, most notably in the morning, and stromal and epithelial edema caused by relatively low tear film osmolality. FED has been linked to mutations in collagen VIII, a vital component of the Descemet's membrane secreted by endothelial cells. FED is divided into four stages, beginning with early signs of guttae formation and progressing to end-stage subepithelial scarring. The biomicroscopic examination is used to diagnose; other modalities, such as corneal pachymetry, confocal microscopy, and specular microscopy, can be used in conjunction.

• The prevalence of Fuchs endothelial dystrophy (FED) ranges from 2.9% to 5.2% of the >=40 population in the USA.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: